GlassScriptPhysician profile
Charlotte J Sumner
NPI 1811022155
$99,453.98
in general payments reported to CMS, 2019-2025
9 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $15K · 2021: $6,780 · 2022: $17K · 2023: $3,919 · 2024: $28K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,900 · Travel and Lodging: $6,630 · Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,183.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,900.00 |
| Travel and Lodging | $6,629.65 |
| Food and Beverage | $902.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $44,937.28 | 2019-2025 | Spinraza |
| F. Hoffmann-La Roche Ag | $30,141.25 | 2019-2024 | |
| Genentech USA, INC. | $9,506.78 | 2019-2024 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $4,101.11 | 2020-2023 | Zolgensma |
| Sarepta Therapeutics, INC. | $3,750.00 | 2020 | |
| Regeneron Pharmaceuticals, INC. | $3,618.66 | 2023 | |
| Genentech, INC. | $3,178.88 | 2020-2023 | Evrysdi |
| Argenx US, INC. | $195.94 | 2024-2025 | Vyvgart |
| Novartis Pharmaceuticals Corporation | $24.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlotte Sumner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.